Lipid abnormalities in HIV/hepatitis C virus-coinfected patients

HIV Medicine

Volumn 7, Issue 8, 2006, Pages 530-536

  Bedimo, Roger ^a,b   Ghurani, R ^a   Nsuami, M ^c   Turner, D ^b   Kvanli, M B ^b   Brown, G ^a,b   Margolis, D ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Coinfection; Dyslipidaemia; Hepatitis C virus; HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DIET RESTRICTION; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID ANALYSIS; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; RISK FACTORS; TEXAS;

EID: 33751013759     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00416.x     Document Type: Article

References (28)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001; 32: 1207-1214.
3. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-837.
4. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
5. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
6. Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: It all depends on the definition. HIV Med 2001; 2: 174-180.
7. Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr 2001; 27: 443-449.
8. Sekhar RV, Jahoor F, White AC et al. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002; 283: E332-E337.
9. Balasubramanyam A, Sekhar RV, Jahoor F, Jones PH, Pownall HJ. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: A model of 'systemic steatosis'. Curr Opin Lipidol 2004; 15: 59-67.
10. Smith DK, Gardner LI, Phelps R et al. Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-99. J Urban Health 2003; 80: 676-688.
11. Lewden C, Salmon D, Morlat P et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: Emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34: 121-130.
12. Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-98. J Infect Dis 2002; 186: 1023-1027.
13. Duong M, Petit JM, Piroth L et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 245-250.
14. Rodriguez-Guardado A, Maradona JA, Asensi V, Carton JA, Casado L. Hepatitis C virus in patients with HIV infection and lipodystrophy. J Acquir Immune Defic Syndr 2003; 32: 348-349.
15. Collazos J, Mayo J, Ibarra S, Cazallas J. Hyperlipidemia in HIV-infected patients: The protective effect of hepatitis C virus co-infection. AIDS 2003; 17: 927-929.
16. Di Giambenedetto S, Baldini F, Cingolani A, Tamburrini E, Cauda R, De Luca A. The influence of hepatitis c virus coinfection on the risk of lipid abnormalities in a cohort of HIV-1-infected patients after initiation of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004; 36: 641-642.
17. Patroni A, Torti C, Tomasoni L et al. Effect of highly active antiretroviral therapy (HAART) and hepatitis C co-infection on hyperlipidemia in HIV-infected patients: A retrospective longitudinal study. HIV Clin Trials 2002; 3: 451-461.
18. Montes ML, Pulido F, Barros C et al. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: Frequency, characterization and risk factors. J Antimicrob Chemother 2005; 55: 800-804.
19. Richter A, Pladevall M, Manjunath R et al. Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: A retrospective cohort study. HIV Med 2005; 6: 79-90.
20. Vigouroux C, Maachi M, Nguyen TH et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003; 17: 1503-1511.
21. Polgreen PM, Fultz SL, Justice AC et al. Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people. HIV Med 2004; 5: 144-150.
22. Bonfanti P, Gulisano C, Ricci E et al. Risk factors for lipodystrophy in the CISAI cohort. Biomed Pharmacother 2003; 57: 422-427.
23. Carr A. HIV lipodystrophy: Risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17 (Suppl. 1): S141-S148.
24. Lichtenstein KA, Delaney KM, Armon C et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32: 48-56.
25. Bausserman LL, Tashima KT, DiSpigno M, Maceroni D, Carpenter CC. Racial differences in serum lipids in HIV+women treated with protease inhibitor regimens. HIV Clin Trials 2004; 5: 399-405.
26. O'Meara JG, Kardia SL, Armon JJ, Brown CA, Boerwinkle E, Turner ST. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med 2004; 164: 1313-1318.
27. Siagris D, Christofidou M, Theocharis GJ et al. Serum lipid pattern in chronic hepatitis C: Histological and virological correlations. J Viral Hepat 2006; 13: 56-61.
28. Andre P, Perlemuter G, Budkowska A, Brechot C, Lotteau V. Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis 2005; 25: 93-104.